---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-283212"
form_type: "8-K"
ticker: "BCAB"
cik: "0001826892"
company_name: "BioAtla, Inc."
filed_at: "2024-12-20T23:59:59+00:00"
generated_at: "2026-05-29T00:28:54.605316+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BioAtla raises $9.2M in registered direct offering to fund mid-stage TCE and ADC programs

## Summary
- Sold 9,679,158 shares and accompanying warrants at $0.9520/unit; gross proceeds ~$9.2M.
- Warrants exercisable at $1.19/share for 5.5 years, beginning 6 months after issuance.
- Proceeds to fund BA3182 Phase 1 dose escalation data (2Q25) and Phase 2 expansion data (1H26).
- Proceeds also to fund mecbotamab vedotin Phase 2B data in mKRAS NSCLC (1H26).
- Officers and directors subject to 75-day lock-up; company restricted on equity issuance for 75 days.

## SEC filing metadata
- accession: 0001193125-24-283212
- form_type: 8-K
- ticker: BCAB
- cik: 0001826892
- company_name: BioAtla, Inc.
- filed_at: 2024-12-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826892/000119312524283212/0001193125-24-283212-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826892/000119312524283212/d823541d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-283212
- JSON: https://secwatch.observer/filing/0001193125-24-283212.json
- Plain text: https://secwatch.observer/filing/0001193125-24-283212.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.